NEW YORK (GenomeWeb News) – Rosetta Genomics said today it has struck an agreement with the University of California, Irvine, School of Medicine to work together to validate diagnostic tests based on the company’s microRNA technology.
Under the agreement, the CLIA-certified medical school and the company will work together to validate tests that are designed to differentiate squamous from non-squamous lung cancer and to differentiate mesothelioma from adenocarcinoma, as well as to identify cancers of unknown primary origin.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.